2026-08-11 — The German biotech raised undisclosed funding from Nordic Foodtech VC to advance alpaca-derived nanoantibodies delivered through fish feed against…
Hamburg-based AquaNab raised an undisclosed amount from Finnish early-stage fund Nordic Foodtech VC. The startup develops alpaca-derived nanoantibodies delivered through fish feed as precision immunotherapies that cross the intestinal barrier into the bloodstream of Atlantic salmon.
AquaNab initially targets sea lice, a parasite the company says costs global aquaculture around $4 billion a year.
The German biotech raised undisclosed funding from Nordic Foodtech VC to advance alpaca-derived nanoantibodies delivered through fish feed against sea lice.
· Biologicals · Germany · 2 min
Hamburg-based AquaNab raised an undisclosed amount from Finnish early-stage fund Nordic Foodtech VC. The startup develops alpaca-derived nanoantibodies delivered through fish feed as precision immunotherapies that cross the intestinal barrier into the bloodstream of Atlantic salmon.
AquaNab initially targets sea lice, a parasite the company says costs global aquaculture around $4 billion a year.
Source: Tech.eu